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Abstract: TBWSP31 is a novel antitumor protein that was isolated from tartary buckwheat 
water-soluble extracts. The objective of this paper was to investigate the anti-proliferative 
effects of TBWSP31 on breast cancer Bcap37cells and to explore its possible mechanism. 
After treatment of Bcap37 cells with TBWSP31, typical apoptotic morphological changes 
were observed by inverted microscopy and scanning electron microscopy (SEM), such as 
detachment from the culture plate, change to a round shape, cell shrinkage, the absence of 
obvious  microvilli,  plasma  membrane  blebbing,  and  formation  of  apoptotic  bodies. 
Cell-cycle analysis revealed that treatment with TBWSP31 resulted in a G0/G1 arrest and 
prevented the cells from growing from G0/G1 phase to S phase, which was most prominent at 
48 h. The expression of bcl-2 and Fas were detected quantitatively by FCM, which showed 
that TBWSP31 induced-apoptosis may be involved with the participation of Fas and bcl-2. 
These results suggest that TBWSP31 is a potential antitumor compound and that apoptosis 
induced by TBWSP31 is a key antitumor mechanism. 
Keywords: tartary buckwheat; protein; breast cancer cells; apoptosis; antitumor 
 
OPEN ACCESS Int. J. Mol. Sci. 2010, 11                       
 
 
5202 
1. Introduction 
The genus Fagopyrum has about 15 species distributed in different parts of the world [1]. Among 
these species, only two types of buckwheat are used as food around the world: common buckwheat 
(Fagopyrum esculentum Moench) and tartary buckwheat (Fagopyrum tataricum Gaertn.) [2].  
Tartary buckwheat grain, as an important functional food material, is commonly taken in the diet in 
eastern Asian countries [3]. It is well known that tartary buckwheat contains higher rutin and vitamins 
B1, B2, and B6 content than common buckwheat [4,5]. In China, tartary buckwheat is mainly grown in 
some mountainous regions, such as Liang Shan Yi Autonomous region in Sichuan province and Jing 
Zhou in Gui Zhou province [6].  
Buckwheat protein has high biological value due to a well-balanced amino acid pattern and is rich in 
lysine and arginine. Recently, the physiological properties of buckwheat protein have also been studied. 
In  rat  feeding  experiments,  studies  have  proven  that  buckwheat  protein  extract  has 
hypocholesterolemic [7–10], anticonstipation [11] and antiobesity activities [12]. In addition, Liu et al. 
[13] reported that buckwheat protein product had a protective effect against 1,2-dimethyhydrazine 
(DMH)-induced colon carcinogenesis in rats by reducing cell proliferation. Kayashita et al. reported that 
consumption  of  the  buckwheat  protein  extract  retarded  7,12-dimetylbenz  (α)  anthracene 
(DMBA)-induced mammary carcinogenesis in rats [14]. 
A tumor is a disease state characterized by uncontrolled proliferation and a loss of apoptosis. Cell 
proliferation and death are involved in the maintenance of homeostasis in normal tissues, and cell death 
is often inhibited in tumors with a higher cell proliferation rate  [15].  Apoptosis  is  the  process  of 
programmed cell death through a tightly controlled program that plays important roles in many normal 
processes,  ranging  from  fetal  development  to  adult  tissue  homeostasis  [16].  Thus,  modulating 
apoptosis may be useful in the management and therapy or prevention of cancer. Apoptotic induction 
has been a new target for innovative mechanism based drug discovery. Compounds that block or 
suppress the proliferation of tumor cells by inducing apoptosis are considered to have potential as 
antitumor  agents  [17].  Apoptosis  and  necrosis  are  two  different  types  of  cell  death  via  distinct 
morphological and biochemical processes [18,19]. 
Breast  cancer  is  the  most  common  cancer  affecting  women  worldwide.  It  accounts  for 
approximately  25%  of  all  female  malignancies  with  a  higher  prevalence  in  developed  countries. 
Incidence rates continue to increase especially in the USA, Canada, the Nordic countries, Singapore 
and Japan, with over one million new cases reported each year worldwide [20]. An attractive method 
for breast carcinoma chemotherapy is the use of pharmaceutical agents that induce death of breast tumor 
cells to overcome proliferation. It is important to screen apoptotic inducers from plants, either in the 
form of crude extracts or as components isolated from them. 
In our previous study, the effective antitumor protein (coded as TBWSP31) was isolated and purified 
from Chinese tartary buckwheat water-soluble extracts, and the antitumor mechanism of TBWSP31 was 
not clearly elucidated [21]. The antitumor effect of TBWSP31 was determined by MTT assay and we 
tested a number of different cell lines, such as Bel-7402 (human liver cancer cells), SGC-7901 (human 
gastric cancer cells), MDA-MB-231 (human breast cancer cells), Bcap37 (human breast cancer cells), 
MCF-7 (human breast cancer cells) and KB (human mouth carcinoma cells). Of the cancer cells tested, 
the most sensitive tumor cell to TBWSP31 was the human mammary cancer cell (unpublished data). The Int. J. Mol. Sci. 2010, 11                       
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main objective of this study was to investigate  the mechanism underlying the anti-tumor effect of 
TBWSP31 on the human breast cancer cell line Bcap37 and to explore whether the effect is mediated 
via an apoptotic mechanism. In this paper, morphological changes of Bcap37 cells were observed by 
inverted microscopy and scanning electron microscopy (SEM). Furthermore, the cell cycle and the 
expression of bcl-2 and Fas were analyzed using flow cytometry.  
2. Results and Discussion  
2.1. Trypan Blue Exclusion Test 
Figure 1 shows the effect of TBWSP31 treatment on Bcap37 cells as a growth curve. The dynamic 
change of Bcap37 cell proliferation in the presence of TBWSP31 is reflected by the cells’ growth 
curve. The effect of TBWSP31 treatment on Bcap37 cell growth was determined using the trypan blue 
exclusion test after 96 h of incubation. As shown in Figure 1, the number of living untreated Bcap37 
cells increased linearly with the increase of incubation time. However, when Bcap37 cells were treated 
with  200  μg/mL  of  TBWSP31,  the  living  cell  number  scarcely  increased  over  the  length  of  the 
experiment. The cells treated with 100 μg/mL of TBWSP31 showed slow growth and the cell growth 
curve reached a plateau before the incubation time reached 72 h. Furthermore, the number of living 
Bcap37 cells treated with 50 μg/mL increased until the incubation time of 72 h had been reached, and 
then decreased, which indicated that the inhibitory effect of TBWSP31 on Bcap37 cell proliferation was 
not due to direct killing of Bcap37 cells. In this part, we only investigated the effect of higher doses of 
TBWSP31 (50–200 μg/mL) on the growth of Bcap37 cells. The inhibition effect of lower concentrations 
of  TBWSP31  (5–50  μg/mL)  on  the  proliferation  of  Bcap37  cells  was  assessed  by  colorimetric 
MTT-assay in our previous study. For the rest of the current paper, lower concentrations of TBWSP31 
were  used  because  Flow  cytometry  (FCM)  analysis  needed  a  minimum  amount  of  cells  per 
experimental condition. 
Figure 1. Effect of TBWSP31 treatment on Bcap37 cell growth. Bcap37 cells were treated 
with different concentration of TBWSP31 for 24, 48, 72 and 96 h. Data are shown as 
means ±  SD (n = 4). 
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2.2. Morphological Observations by Inverted Microscopy 
Figure 2 shows the morphology changes of Bcap37 cells after treatment with TBWSP31 as observed 
by inverted microscopy. Bcap37 cells were cultured with 0 (control) or 10 μg/mL of TBWSP31 for 
24 h. Under an inverted microscope, cell shape and changes can be clearly observed. As shown in 
Figure 2A, cells in the control group showed adherent growth and a regular polygon shape, with very 
few  round  cells.  The  growth  speed  of  the  control  Bcap37  cells  was  higher  than  that  of  the 
TBWSP31-treated cells, indicating that TBWSP31 inhibited Bcap37 cell proliferation. Compared to the 
control, marked morphological changes were observed in the cells treated with 10 μg/mL of TBWSP31 
for 24 h (Figure 2B). The adherent ability of Bcap37 cells became worse and the shape became round. 
Additionally, only few cells remained attached and the number of floating smaller cells increased in 
the medium after 24 h incubation with 10 μg/mL of TBWSP31, indicating the possibility of   
apoptosis occurrence [22]. 
Figure 2. The TBWSP31-dependent morphology changes of Bcap37 cells observed under 
an inverted microscope. Bcap37 cells were cultured with (A) 0 μg/mL of TBWSP31 for 
24 h; (B) Bcap37 cells were cultured with 10 μg/mL of TBWSP31 for 24 h. 
 
(A) control, 200×  
 
(B) 10 μg/mL, 200×  Int. J. Mol. Sci. 2010, 11                       
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2.3. Morphological Observation by SEM 
To further investigate whether TBWSP31 mediated cell death of Bcap37 cells is due to an apoptotic 
mechanism, the surface morphological changes that occurred with 20 μg/mL of TBWSP31 treatment 
for  48 h  were  observed  under  SEM.  Figure  3  shows  the  morphological  changes  of  Bcap37  cells 
observed by SEM. 
Figure 3. The morphological changes of Bcap37 cells as observed by scanning electron 
microscopy (SEM; 8000× ).  Two images of Bcap37 cells cultured  with  0  μg/mL (A) or 
20 μg/mL (B) of TBWSP31 for 48 h.  
 
(A) 
 
(B) 
The control group showed untreated cells with numerous microvilli over the surface of the cells and 
intact cells (Figure 3A). In contrast, cells treated with TBWSP31 exhibited a significant decrease in the 
number of microvilli and an apparent deformation (Figure 3B). The surface of Bcap37 cells became 
relatively smooth with no obvious microvilli, and some irregular blebs and apoptotic bodies were seen 
in cell membranes after treatment. Membrane blebbing is one of a series of distinctive morphological 
events  during  apoptosis.  It  has  been  reported  to  be  associated  with  cytoplasmic  and  nuclear Int. J. Mol. Sci. 2010, 11                       
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manifestations  of  apoptosis  [23].  Highly  conserved  morphological  changes,  including  membrane 
blebbing  and  cell  shrinkage,  have  been  used  as  morphological  criteria  to  identify  apoptotic  cell 
death [24,25]. Cell shrinkage and plasma membrane blebbing could be observed after incubation of 
Bcap37  cells  with TBWSP31.  Treatment  of Bcap37  cells  with  TBWSP31 resulted  in  significant 
morphological alterations, which are typical characteristics of apoptosis.   
2.4. Cell Cycle Analysis 
Table 1 shows the effect of TBWSP31 on the percentage of Bcap37cells present in each cell cycle 
phase (G0/G1, S, and G2/M). After 24 h incubation with 0 (control), 5 and 10 μg/mL of TBWSP31, the 
cell population in the G0/G1 phase was 53.6%, 57.3% and 68.4%, the cell population in S phase was 
33.5%,  31.4%  and  28.9%,  and  the  cell  population  in  G2/M  phase  was  12.9%,  11.3%  and  2.7%, 
respectively. After 48 h incubation with 5 and 10 μg/mL of TBWSP31, the cell population in the G0/G1 
phase increased to 70.9% and 77.6%, and the cell population in S phase decreased to 28.5% and 21.8%, 
respectively (p < 0.01). These results showed that TBWSP31 could inhibit the growth of Bcap37 cells 
through a cell cycle arrest in the G0/G1 phase, and prevent the cells growing from G0/G1 phase to S phase 
(p < 0.05). In addition, the inhibition effect of TBWSP31 on the proliferation of Bcap37 cells existed in 
a dose- and time-dependent manner. 
Table 1. Effect of TBWSP31 treatment on the Bcap37 cell cycle. 
Time 
(h) 
Concentration 
(μg/mL) 
G0/G1 
(%) 
S 
(%) 
G2/M 
(%) 
24  control  53.6  33.5  12.9 
5  57.3  31.4  11.3 
10  68.4  28.9  2.7 
48  control  54.9  32.7  12.4 
5  70.9  28.5  0.6 
10  77.6  21.8  0.7 
2.5. Effect of TBWSP31 on Levels of bcl-2 and Fas Proteins in Bcap37 Cells 
The effect of TBWSP31 on the levels of bcl-2 and Fas proteins in Bcap37 cells is shown in Figure 4. 
The level of bcl-2 decreased dramatically from 71.5% (0 μg/mL, control) to 46.7% and 32.3% when 
Bcap37  cells  were  treated  with  5 μg/mL and 10  μg/mL of TBWSP31, respectively (p < 0.01) (see 
Figure 4A). In contrast, the levels of Fas protein increased significantly after TBWSP31 treatment: 
from 2.83% (0 μg/mL, control) to 13.3% (5 μg/mL) and 27.0% (10 μg/mL) (p < 0.01) (Figure 4B). 
These results showed that TBWSP31 treatment induced a significant decrease of bcl-2 expression and 
increase  of Fas  expression  after  48  h  in  a  dose-dependent  manner. Cell apoptosis is regulated by 
anti-apoptotic and pro-apoptotic effectors, involving a large number of biomolecules. Bcl-2 is known to 
be an upstream effector molecule in the apoptotic pathway and is identified as a potent suppressor of 
apoptosis  [26]. Fas  protein,  a  glycosylated  45-kD  transmembrane  receptor,  belongs  to  the  tumor 
necrosis factor receptor family and induces apoptosis [27]. In the present study, the expression of bcl-2 
was  down-regulated  and  the  expression  of  Fas  was  up-regulated.  The  changes  of  these Int. J. Mol. Sci. 2010, 11                       
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proteins-correlated  apoptosis  expressions  suggested  that  TBWSP31  induced-apoptosis  may  be 
involved with the participation of Fas and Bcl-2.   
Figure 4. The alteration  of bcl-2  (A) and Fas  (B)  protein levels of Bcap37 cells after 
treatment with TBWSP31, as determined by flow cytometry. Bcap37 cells were treated with 
0 (control; left panels), 5 (middle panels) and 10 μg/mL (right panels) of TBWSP31 for 48 h. 
The percentage of the Bcl-2 and Fas protein are shown at the top right of each panel. 
 
(A) control            (A) 5 μg/mL, 48 h              (A) 10 μg/mL, 48 h 
 
(B) control                   (B) 5 μg/mL, 48 h        (B) 10 μg/mL, 48 h 
 
3. Experimental Section  
3.1. Materials 
Tartary buckwheat flour was obtained from the milling factory for minor crops in Liang Shan region 
in Sichuan province. Flour was defatted for 24 h with n-hexane under continuous stirring, air-dried at 
room temperature, and stored at 4 °C  until used. Int. J. Mol. Sci. 2010, 11                       
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3.2. Preparation of TBWSP31 
TBWSP31  was  isolated  from  tartary  buckwheat  water-soluble  extracts  and  purified  by 
DEAE-Sepharose FF anion exchange, Sephadex G-100 gel filtration and Sephacryl S-200 gel filtration 
column chromatography. 
3.3. Cell Culture 
Human breast cancer (Bcap37) cell culture was maintained in RPMI-1640 medium (Gibco BRL, 
Grand  Island,  NY)  supplemented  with  10%  fetal  bovine  serum  at  37  °C   in  maximal  humidity 
atmosphere containing 5% CO2.  
3.4. Trypan Blue Exclusion Test 
The effect of TBWSP31 treatment on  Bcap37 cells growth was determined by the trypan blue 
exclusion test [28]. Bcap37 cells were plated in 24-well culture plates at 5 ×  10
4 cells/well and were 
treated with serial dilutions of TBWSP31 in quadruplicate. Wells containing different dilutions were 
selected to be counted every 24 h and cells that excluded trypan blue were counted in a Neubauer 
chamber. The growth curve of Bcap37 cells was drawn according to their average value.   
3.5. Light Microscopy 
Bcap37 cells were seeded in RPMI-1640 containing 10% FBS and treated with 0 (control) and 
10 μg/mL of TBWSP31 for 24 h. The cellular morphology was directly observed using an inverted 
microscope at the indicated times. 
3.6. SEM 
Bcap37 cells were seeded in RPMI-1640 containing 10% FBS and treated with 0 (control) and 
20 μg/mL of TBWSP31 for 48  h. After incubation, cells were collected and fixed in 2.5% (V/V) 
glutaraldehyde at 4 °C  for SEM analysis [29]. Fixed cells were rinsed in 0.1 M phosphate buffer, pH 7.2 
and post-fixed with 1% osmium tetroxide. Cells were rinsed in phosphate buffer and dehydrated in a 
graded ethanol series of 30, 50, 70, 90, 100% for 20 min. Cells were then critical point-dried from CO2 in 
a critical point dryer (CPD-030, BAL-TEC Co.). The dried cells were affixed to an aluminum stub with 
double-stick tape, coated with gold in an ionic sputter coater (SCD-005, BAL-TEC Co.). They were 
viewed and photographed by scanning electronic microscopy (QUANTA-200, FEI CO.). 
3.7. Quantitative Detection of Cell DNA with Flow Cytometry (FCM) 
Bcap37 cells were seeded in RPMI-1640 containing 10% FBS and treated with 0 (control), 5 and 
10 μg/mL of TBWSP31 for 24 h and 48 h. Cell cycle analysis was performed using a hypotonic solution 
of propidium iodide (PI). Approximate 1 ×  10
6 cells per experimental condition were harvested, washed 
with cold PBS twice and fixed with 70% ice-cold ethanol at −20 °C . After fixation, cells were washed 
twice with PBS, then incubated with 100  µg/mL RNase A for 30 min at 37  ° C and stained with 
100 µg/mL propidium iodide (Sigma Chemical Co) for 30 min at room temperature. DNA fluorescence Int. J. Mol. Sci. 2010, 11                       
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was measured in a Becton Dickinson flow cytometer, and the percentages of cells in G0/G1, S, and G2/M 
phases of the cell cycle were determined using the CellFIT software. 
3.8. Determination of the Expression of bcl-2 and Fas 
Bcap37 cells were seeded in RPMI-1640 containing 10% FBS and treated with 0 (control), 5 and 
10 μg/mL of TBWSP31 for 48 h. After incubation, cells were fixed with 4% paraformaldehyde at room 
temperature for 30 min, washed with PBS, and then permeabilized with 0.2% Triton X-100. The cells 
were then incubated in PBS with either bcl-2 or Fas for 30 min at 37 ° C. After two washes, the cells were 
incubated in PBS with the secondary FITC-conjugated goat anti-rat IgG for an additional 30 min at 4 °C  
in the dark. Subsequently, the cells were washed twice with PBS and analyzed by flow cytometry. 
3.9. Statistical Analysis 
Statistical analyses were performed using the SAS 8.1 software package (SAS Institute, Cary, North 
Carolina). Statistical significance was determined by analysis of variance (ANOVA) (p < 0.05). 
4. Conclusions 
In this work we investigated the antitumor mechanism of TBWSP31 on the human breast cancer cell 
line Bcap37 by  inverted  microscopy,  scanning  electron  microscopy  and  flow cytometry.  Typical 
apoptotic morphological changes were observed after incubation of Bcap37 cells with TBWSP31, such 
as detachment from the culture plate, no obvious microvilli, plasma membrane blebbing, and formation 
of apoptotic bodies. Cell-cycle analysis revealed that treatment with TBWSP31 resulted in G0/G1 arrest 
and prevented the cells from growing from G0/G1 phase to S phase. The expression of bcl-2 and Fas were 
detected quantitatively by FCM, which showed that TBWSP31 induced-apoptosis  may  be involved 
with up-regulation of Fas expression and down-regulation of bcl-2 expression. From the above facts, 
we conclude that TBWSP31 could inhibit the growth of Bcap37 cells via induction of apoptosis. 
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